GHK-Cu occupies a slightly different niche than most peptides on this site: it's the one most commonly found in mainstream skincare products, not just injectable research-chemical vials, and its evidence base reflects that different, more topical-focused history.
What It Is
GHK-Cu is a naturally occurring copper-binding peptide found in human plasma, saliva, and urine, that declines with age. It's been studied for decades for its role in wound healing, collagen production, and antioxidant activity at the tissue level, and synthetic versions are now widely used in both topical cosmetic formulations and, less commonly, injectable research protocols.
Regulatory Status
As a topical cosmetic ingredient, GHK-Cu falls under FDA cosmetic regulation, a much lighter framework than drug approval, which doesn't require proof of efficacy before marketing. As an injectable product, it is not FDA-approved as a drug and is sold through research-chemical channels for that use.
What the Research Shows
GHK-Cu has a genuinely larger body of published research than most compounds discussed on this site, including both older cell-culture and animal wound-healing studies and a number of human studies specifically evaluating topical formulations for skin appearance, showing improvements in measures like fine lines and skin firmness in some trials. Evidence for injectable use is considerably thinner and relies much more heavily on the older mechanistic and animal research rather than dedicated human injectable trials.
Safety Considerations
Topical GHK-Cu is generally well tolerated, with occasional skin irritation reported. Injectable use carries the same general unknowns as other unregulated injectable peptides, no standardized human dosing, no large safety trials for that specific route, and quality variability tied to an unregulated supply chain.
The Bottom Line
GHK-Cu is a good example of a peptide where the evidence quality actually depends heavily on the intended use. Its topical cosmetic research is more substantial than most peptides on this site; its evidence for injectable use is not, and the two shouldn't be assumed to carry equal weight just because they involve the same molecule.
Why the Delivery Route Changes the Risk Calculus
It's worth being specific about why topical and injectable GHK-Cu shouldn't be treated as equally low-risk. A topical cream reaches only the outer skin layers at a controlled, generally low concentration, and decades of cosmetic use have generated a reasonably reassuring, if informal, real-world safety record for that specific application. Injecting the same peptide bypasses skin entirely, introducing it systemically at a different concentration and absorption profile than anything the topical research actually studied, which means the topical safety record shouldn't be assumed to carry over directly to injectable use, even though it's chemically the same molecule.